Condition
Advanced Gastrointestinal Tumors
Total Trials
5
Recruiting
0
Active
0
Completed
2
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 1 (4)
Trial Status
Terminated2
Completed2
Unknown1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04612712Phase 1TerminatedPrimary
A Phase 1/2 Study of Donafenib in Combination With KN046 in Advanced Gastrointestinal Tumors
NCT06197178Phase 1TerminatedPrimary
A Study of LCAR-G08 in Subjects With Advanced Gastrointestinal Tumors Expressing Guanylyl Cyclase C (GCC)
NCT01916447Phase 1CompletedPrimary
A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.
NCT03977077Not ApplicableUnknownPrimary
Treatment of Advanced Gastrointestinal Tumors With Albumin Taxol
NCT01927965Phase 1CompletedPrimary
Study of Minnelide™ in Patients With Advanced GI Tumors
Showing all 5 trials